Quite the ensemble.

Johnson & Johnson threw its single-shot COVID-19 vaccine in the ring last week with an emergency use authorization submission after the phase 3 ENSEMBLE trial met its primary endpoints by demonstrating 66% efficacy in preventing moderate+ disease (with pneumonia, DVT, shortness of breath, low O2 sats, etc) and 100% efficacy in preventing hospitalization and death. | J&J 2021

Comments

Popular Posts